Colistin and Polymyxin B in Critical Care

Falagas, 2006, The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature, Clin Med Res, 4, 138, 10.3121/cmr.4.2.138

Afzal-Shah, 1998, Worldwide emergence of carbapenem resistant Acinetobacter spp, J Antimicrob Chemother, 41, 576, 10.1093/jac/41.5.576

Gales, 2001, Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997–1999), Clin Infect Dis, 32, S104, 10.1086/320183

Falagas, 2006, Polymyxins: old antibiotics come back, Lancet, 367, 633, 10.1016/S0140-6736(06)68241-X

Jones, 2001, Resistance patterns among nosocomial pathogens: trends over the past few years, Chest, 119, 397S, 10.1378/chest.119.2_suppl.397S

Livermore, 2004, The need for new antibiotics, Clin Microbiol Infect, 10, 1, 10.1111/j.1465-0691.2004.1004.x

Hsueh, 2001, Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan, Microb Drug Resist, 7, 373, 10.1089/10766290152773383

Hanberger, 2001, Surveillance of antibiotic resistance in European ICUs, J Hosp Infect, 48, 161, 10.1053/jhin.2001.0987

Waterer, 2001, Increasing threat of gram-negative bacteria, Crit Care Med, 29, N75, 10.1097/00003246-200104001-00004

Fridkin, 1999, Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals, Clin Infect Dis, 29, 245, 10.1086/520193

Landman, 2002, Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned, Arch Intern Med, 162, 1515, 10.1001/archinte.162.13.1515

Davin-Regli, 1996, Molecular epidemiology of Enterobacter aerogenes acquisition: one-year prospective study in two intensive care units, J Clin Microbiol, 34, 1474, 10.1128/JCM.34.6.1474-1480.1996

Storm, 1977, Polymyxin and related peptide antiibiotics, Annu Rev Biochem, 46, 723, 10.1146/annurev.bi.46.070177.003451

Kumazawa, 2002, The history of antibiotics: the Japanese story, J Infect Chemother, 8, 125, 10.1007/s101560200022

Evans, 1999, Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria, Ann Pharmacother, 33, 960, 10.1345/aph.18426

Koyama, 1950, A new antibiotic “colistin” produced by spore-forming soil bacteria, J Antibiot (Tokyo), 3, 457

Reed, 2001, The pharmacokinetics of colistin in patients with cystic fibrosis, J Clin Pharmacol, 41, 645, 10.1177/00912700122010537

Rodger, 1965, Treatment of infections with colistimethate sodium (coly-mycin), Can Med Assoc J, 93, 143

Lamb, 1968, Colistin sulphate in the treatment of specific bacterial intestinal infections, Scott Med J, 13, 9, 10.1177/003693306801300102

Meleney, 1961, Some laboratory and clinical observations on coly-mycin (colistin) with particular reference to Pseudomonas infections, Surg Gynecol Obstet, 112, 211

Fekety, 1962, The treatment of gram-negative bacillary infections with colistin: the toxicity and efficacy of large doses in forty-eight patients, Ann Intern Med, 57, 214, 10.7326/0003-4819-57-2-214

Elwood, 1966, Acute renal failure associated with sodium colistimethate treatment, Arch Intern Med, 118, 326, 10.1001/archinte.1966.00290160026006

Brown, 1970, Acute renal failure due to overdosage of colistin, Med J Aust, 2, 923, 10.5694/j.1326-5377.1970.tb63262.x

Parisi, 1965, Apnea during treatment with sodium colistimethate, JAMA, 94, 298, 10.1001/jama.1965.03090160076026

Valenius, 1991, Prevention of chronic Pseudomonas aeruginosa in cystic fibrosis by early treatment, Lancet, 338, 725, 10.1016/0140-6736(91)91446-2

Friis, 1979, Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis, Scand J Infect Dis, 11, 211, 10.3109/inf.1979.11.issue-3.07

Ledson, 1998, Four years' experience of intravenous colomycin in an adult cystic fibrosis unit, Eur Respir J, 12, 592, 10.1183/09031936.98.12030592

Levin, 1999, Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Clin Infect Dis, 28, 1008, 10.1086/514732

Garnacho-Montero, 2003, Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP, Clin Infect Dis, 36, 1111, 10.1086/374337

Wootton, 2005, Development of a novel assay method for colistin sulphomethate, Clin Microbiol Infect, 11, 243, 10.1111/j.1469-0691.2005.01076.x

Bergen, 2006, Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 50, 1953, 10.1128/AAC.00035-06

Li, 2005, Evaluation of colistin as an agent against multi-resistant gram-negative bacteria, Int J Antimicrob Agents, 25, 11, 10.1016/j.ijantimicag.2004.10.001

Li, 2003, Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis, J Antimicrob Chemother, 52, 987, 10.1093/jac/dkg468

Li, 2005, Difficulty in assaying colistin methanesulphonate, Clin Microbiol Infect, 11, 773, 10.1111/j.1469-0691.2005.01218.x

Falagas, 2005, Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections, Clin Infect Dis, 40, 1333, 10.1086/429323

Cooperstock, 1974, Inactivation of endotoxin by polymyxin B, Antimicrob Agents Chemother, 6, 422, 10.1128/AAC.6.4.422

Amsden, 2000, Tables of antimicrobial agent pharmacology, 578

MacKay, 1964, Serum concentrations of colistin in patients with normal and impaired renal function, N Engl J Med, 270, 394, 10.1056/NEJM196402202700804

Goodwin, 1968, The effects of renal impairment, peritoneal dialysis, and hemodialysis on serum sodium colistimethate levels, Ann Intern Med, 68, 984, 10.7326/0003-4819-68-5-984

Owen, 2007, In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates, J Antimicrob Chemother, 59, 473, 10.1093/jac/dkl512

Tan, 2006, The in-vitro activity of colistin in gram-negative bacteria, Singapore Med J, 47, 621

Catchpole, 1997, A reassessment of the in-vitro activity of colistin sulphomethate sodium, J Antimicrob Chemother, 39, 255, 10.1093/jac/39.2.255

Hogardt, 2004, Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients, J Antimicrob Chemother, 54, 1057, 10.1093/jac/dkh470

Horton, 1982, Polymyxin B, colistin, and sodium colistimethate, Med Clin North Am, 66, 135, 10.1016/S0025-7125(16)31447-X

Li, 2006, Defining the dosage units for colistin methanesulfonate: urgent need for international harmonization, Antimicrob Agents Chemother, 50, 4231, 10.1128/AAC.00756-06

Curtis, 1968, Colistin sulphomethate sodium administration in the presence of severe renal failure and during haemodialysis and peritoneal dialysis, Br Med J, 1, 484, 10.1136/bmj.1.5590.484

Greenberg, 1967, Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis: tetracycline, chloramphenicol, kanamycin, and colistimethate, Ann Intern Med, 66, 465, 10.7326/0003-4819-66-3-465

Falagas, 2006, Use of international units when dosing colistin will help decrease confusion related to various formulations of the drug around the world, Antimicrob Agents Chemother, 50, 2274, 10.1128/AAC.00101-06

Li, 2001, In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis, Antimicrob Agents Chemother, 45, 781, 10.1128/AAC.45.3.781-785.2001

Tam, 2005, Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa, Antimicrob Agents Chemother, 49, 3624, 10.1128/AAC.49.9.3624-3630.2005

Itokazu, 1996, Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program, Clin Infect Dis, 23, 779, 10.1093/clinids/23.4.779

Jain, 2004, Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians, Ann Pharmacother, 38, 1449, 10.1345/aph.1D592

Goverman, 2007, Intravenous colistin for the treatment of multi-drug resistant, gram-negative infection in the pediatric population, J Burn Care Res, 28, 421, 10.1097/BCR.0B013E318053D346

Falagas, 2005, Treatment of multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii pneumonia, J Cyst Fibros, 4, 149, 10.1016/j.jcf.2005.02.003

Reina, 2005, Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study, Intensive Care Med, 31, 1058, 10.1007/s00134-005-2691-4

Falagas, 2006, Effectiveness and nephrotoxicity of colistin monotherapy versus colistin/meropenem combination therapy for multidrug-resistant gram-negative bacterial infections, Clin Microbiol Infect, 12, 1227, 10.1111/j.1469-0691.2006.01559.x

Mentzelopoulos, 2007, Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant Pseudomonas aeruginosa, Intensive Care Med, 33, 1524, 10.1007/s00134-007-0683-2

Markou, 2003, Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients, Crit Care, 7, R78, 10.1186/cc2358

Karabinis, 2004, Colistin for Klebsiella pneumoniae–associated sepsis, Clin Infect Dis, 38, e7, 10.1086/380461

Michalopoulos, 2005, Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin, Scand J Infect Dis, 37, 142, 10.1080/00365540410020776-1

Kopterides, 2007, Exposure to fluoroquinolones is a risk factor for polymyxins-only susceptible (POS) Acinetobacter baumanniibacteremia in critically ill patients, Int J Antimicrob Agents, 30, 409, 10.1016/j.ijantimicag.2007.06.026

Berlana, 2005, Use of colistin in the treatment of multiple-drug-resistant gram-negative infections, Am J Health Syst Pharm, 62, 39, 10.1093/ajhp/62.1.39

Falagas, 2007, Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence, Int J Antimicrob Agents, 29, 9, 10.1016/j.ijantimicag.2006.08.024

Bauldoff, 1997, Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation, Transplantation, 64, 748, 10.1097/00007890-199709150-00015

Pereira, 2007, Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant gram-negative bacilli with inhaled polymyxin B, Diagn Microbiol Infect Dis, 58, 235, 10.1016/j.diagmicrobio.2007.01.008

Horianopoulou, 2005, Effect of aerosolized colistin on multidrug-resistant Pseudomonas aeruginosa in bronchial secretions of patients without cystic fibrosis, J Chemother, 17, 536, 10.1179/joc.2005.17.5.536

Hamer, 2000, Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin, Am J Respir Crit Care Med, 162, 328, 10.1164/ajrccm.162.1.9910071

Michalopoulos, 2005, Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis, Crit Care, 9, R53, 10.1186/cc3020

Kwa, 2005, Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, Clin Infect Dis, 41, 754, 10.1086/432583

Paramythiotou, 2007, Post-surgical meningitis due to multiresistant Acinetobacter baumannii: effective treatment with intravenous and/or intraventricular colistin and therapeutic dilemmas, Med Mal Infect, 37, 124, 10.1016/j.medmal.2006.11.011

Schina, 2006, Successful treatment of multidrug-resistant Pseudomonas aeruginosa meningitis with intravenous and intrathecal colistin, Int J Infect Dis, 10, 178, 10.1016/j.ijid.2005.03.005

Quinn, 2005, Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection, Ann Pharmacother, 39, 949, 10.1345/aph.1E485

Benifla, 2004, Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E, J Antimicrob Chemother, 54, 290, 10.1093/jac/dkh289

Fernandez-Villadrich, 1999, Successful treatment of ventriculitis due to carbapenem resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium, Clin Infect Dis, 28, 916, 10.1086/517243

Gump, 2005, Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis, J Neurosurg, 102, 915, 10.3171/jns.2005.102.5.0915

Ng, 2006, Cure of multiresistant Acinetobacter baumannii central nervous system infections with intraventricular or intrathecal colistin: case series and literature review, J Antimicrob Chemother, 58, 1078, 10.1093/jac/dkl347

Falagas, 2006, Toxicity of polymyxins: a systematic review of the evidence from old and recent studies, Crit Care, 10, R27, 10.1186/cc3995

Falagas, 2005, Nephrotoxicity of intravenous colistin: a prospective evaluation, Int J Antimicrob Agents, 26, 504, 10.1016/j.ijantimicag.2005.09.004

Falagas, 2005, Toxicity after prolonged (more than four weeks) administration of intravenous colistin, BMC Infect Dis, 5, 1, 10.1186/1471-2334-5-1

Perkins, 1964, Apnea with intramuscular colistin therapy, JAMA, 190, 421, 10.1001/jama.1964.03070180019004

Anthony, 1966, Apnea due to intramuscular colistin therapy: report of a case, Ohio State Med J, 62, 336

Inoue, 1995, Allergic contact dermatitis from colistin, Contact Derm, 33, 200, 10.1111/j.1600-0536.1995.tb00548.x

Alothman, 2005, Bronchial constriction and inhaled colistin in cystic fibrosis, Chest, 127, 522, 10.1378/chest.127.2.522

Sobieszczyk, 2004, Combination therapy with polymyxin B for the treatment of multidrug-resistant gram-negative respiratory tract infections, J Antimicrob Chemother, 54, 566, 10.1093/jac/dkh369

Holloway, 2006, Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit, Ann Pharmacother, 40, 1939, 10.1345/aph.1H353

Sarria, 2004, Use of intravenous polymyxin B during continuous venovenous hemodialysis, Eur J Clin Microbiol Infect Dis, 23, 340, 10.1007/s10096-004-1106-8

Antoniadou, 2007, Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster, J Antimicrob Chemother, 59, 786, 10.1093/jac/dkl562

Kollef, 2003, An empirical approach to the treatment of multidrug-resistant ventilator-associated pneumonia, Clin Infect Dis, 36, 1119, 10.1086/374342